Home Cart Sign in  
Chemical Structure| 942123-43-5 Chemical Structure| 942123-43-5

Structure of Inarigivir soproxil
CAS No.: 942123-43-5

Chemical Structure| 942123-43-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SB-9200 has a broad-spectrum antiviral activity against RNA viruses including hepatitis C virus (HCV), norovirus, respiratory syncytial virus and influenza and has demonstrated activity against hepatitis B virus (HBV) in vitro and in vivo.

Synonyms: Sb-9200; GS-9992; SB9200

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Inarigivir soproxil

CAS No. :942123-43-5
Formula : C25H34N7O13PS
M.W : 703.62
SMILES Code : O=C(OCSP(O[C@@H]1[C@@H](CO)O[C@@H](N(C(N2)=O)C=CC2=O)[C@@H]1OC)(OC[C@H]3O[C@@H](N4C=NC5=C(N)N=CN=C45)C[C@@H]3O)=O)OC(C)C
Synonyms :
Sb-9200; GS-9992; SB9200
MDL No. :MFCD31715418

Safety of Inarigivir soproxil

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human THP-1 macrophages 10 µM 3 days To evaluate the effect of Inarigivir on the bactericidal activity of THP-1 macrophages against MTB. Results showed that Inarigivir significantly enhanced the bactericidal function of macrophages. Front Immunol. 2020 Dec 7;11:592333
Mouse bone marrow-derived macrophages (MФs) 10 µM 18 hours To evaluate the effect of Inarigivir on the secretion of IL-12, TNF-α, and IFN-β by BCG-infected macrophages. Results showed that Inarigivir significantly increased the secretion of these cytokines. Front Immunol. 2020 Dec 7;11:592333
SW620 cells 80 µM SB9200 significantly reduced cell viability and proliferation, and inhibited migration and invasion of SW620 cells. Int J Oncol. 2022 Oct;61(4):120
HCT116 cells 80 µM SB9200 significantly reduced cell viability and proliferation, and inhibited migration and invasion of HCT116 cells. Int J Oncol. 2022 Oct;61(4):120

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Mouse model of tuberculosis Subcutaneous injection 25 µg/dose/mouse Single immunization, infected with MTB 4 weeks later To evaluate the protective effect of Inarigivir as an adjuvant for BCG vaccine against tuberculosis. Results showed that Inarigivir significantly enhanced the protective efficacy of BCG vaccine, reducing the lung burden of MTB. Front Immunol. 2020 Dec 7;11:592333

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.42mL

0.28mL

0.14mL

7.11mL

1.42mL

0.71mL

14.21mL

2.84mL

1.42mL

References

 

Historical Records

Categories